Drug rebates are payments that pharmaceutical manufacturers send back to insurers and middlemen after a drug has already been sold, effectively lowering the price the insurer paid. But because these payments happen months after you fill your prescription, they rarely lower what you pay at the pharmacy counter. Understanding this disconnect explains a lot about why drug prices in the U.S. feel so confusing.
The Basic Money Flow
A brand-name drug passes through several hands before it reaches you, and money flows in both directions. Here’s a simplified version using a hypothetical $100 drug, based on figures from the U.S. Department of Labor.
A manufacturer sells the drug to a distributor at its list price, say $100. The distributor marks it up and sells it to a pharmacy, which marks it up again to something like $120. When you fill the prescription, you pay your share (maybe $30 as a copay or coinsurance), and your insurance plan pays the pharmacy the remaining $90.
Then, months later, the manufacturer sends a rebate of perhaps $60 back to the pharmacy benefit manager (PBM), the company that manages drug benefits on behalf of your insurer or employer. The PBM keeps a portion, say $10, and passes the rest back to the plan sponsor. In this example, the plan’s net cost drops from $90 to $50. The total actually paid between the plan and the patient is $80 for a drug with a $100 list price.
The key detail: that rebate arrives long after you’ve already paid your $30. For major brand-name drugs in the U.S., these after-the-fact discounts are substantial. Gross-to-net discounts currently average between 36% and 60% for major brand-name portfolios, meaning manufacturers often collect only 40 to 64 cents of every dollar on the sticker price.
Why Rebates Exist
Rebates are a negotiating tool. When multiple drugs treat the same condition, PBMs use their formulary (the list of covered drugs) as leverage. A manufacturer that offers a bigger rebate can get its drug placed on a preferred tier, meaning patients pay less for it and doctors face fewer paperwork hurdles when prescribing it. A drug that doesn’t offer competitive rebates might land on a higher cost-sharing tier or get excluded from the formulary entirely.
In a preferred formulary agreement, the rebated product might be the only option from its therapeutic class on a closed formulary, or it could sit on a lower-cost tier above its competitors. PBMs also use tools like prior authorization requirements to steer patients toward rebated drugs. The result is a system where manufacturers compete not just on clinical merit but on the size of the discount they’re willing to offer behind the scenes.
The Role of Pharmacy Benefit Managers
PBMs sit at the center of the rebate system. They negotiate with manufacturers on behalf of insurers and large employers, deciding which drugs get favorable placement and what rebates are owed. A frequently cited industry estimate is that PBMs achieve rebates of about 30% off list price across all discounts and fees.
How much of that rebate reaches your employer or insurer? Industry data suggests that roughly 98% of manufacturer rebates in recent years have been passed through to plan sponsors, with PBM operating margins accounting for less than 5% of overall prescription drug costs. However, many contracts don’t require PBMs to disclose the rebates they receive, so self-insured employers sometimes have no idea how much money is flowing back. PBMs also generate revenue through other channels like spread pricing (charging the plan more for a drug than they pay the pharmacy), which can account for 10 to 15% of a PBM’s revenue.
Why You Don’t See the Savings
This is the part that frustrates patients most. If your plan charges you a percentage of the drug’s cost (coinsurance) rather than a flat copay, that percentage is almost always calculated on the list price, not the lower net price after rebates. So you might owe 20 to 40% of a $500 list price even though the insurer’s actual cost, after rebates, is far less.
This structure hits hardest for people on high-cost therapies like biologics, where list prices can run thousands of dollars per month. It also disproportionately affects people in deductible phases of their insurance, who pay full list price until they meet their spending threshold. The rebates eventually benefit the plan (and theoretically help keep premiums from rising as fast), but they don’t reduce your out-of-pocket cost at the pharmacy.
Some plans have started experimenting with point-of-sale rebate models, where the plan estimates the rebate it expects to receive and applies that discount to your cost at the time you fill the prescription. This shifts the savings from an invisible, months-later transaction to something you actually feel at the counter. Medicare has encouraged this approach, and some private plans have adopted it, though it’s far from universal.
How Rebates Work in Medicaid
Medicaid operates under a completely different, mandatory rebate system. To have their drugs covered by any state Medicaid program, manufacturers must sign a national rebate agreement and pay quarterly rebates to states based on a formula set by federal law.
For brand-name drugs, the basic rebate is the greater of two calculations: either the difference between the manufacturer’s average price and its lowest price offered to any buyer, or 23.1% of the average manufacturer price (17.1% for certain pediatric drugs and clotting factors). On top of that, an additional rebate kicks in whenever a drug’s price has grown faster than inflation since its launch date. This inflation penalty means that drugs with steep price increases over the years can owe very large rebates to Medicaid, sometimes bringing the effective price close to zero.
Medicare’s Inflation Rebate Program
Starting in 2023, Medicare gained a new tool through the Inflation Reduction Act. Manufacturers that raise prices on Medicare-covered drugs faster than the general rate of inflation now owe rebates directly to the federal government. This applies to both drugs administered in doctors’ offices (Part B) and drugs dispensed at pharmacies (Part D).
For patients, the practical effect is real. When a Part B drug triggers an inflation rebate, Medicare beneficiaries pay their 20% coinsurance based on a lower, inflation-adjusted amount rather than the higher actual price. This is one of the rare cases where a rebate mechanism directly reduces what a patient owes.
Rebate Walls and Competition
The rebate system creates a counterintuitive problem: it can actually block cheaper drugs from reaching patients. This happens through what the Federal Trade Commission calls “rebate walls.”
Here’s how it works. A dominant manufacturer offers a PBM large rebates, but with a catch: the rebates are conditioned on the PBM giving that drug exclusive or preferred formulary status. If the PBM adds a competing product (say, a lower-cost biosimilar), the original manufacturer can pull its rebates entirely or even claw back rebates already paid. The PBM then faces the full list price on the original drug for every patient it can’t switch to the competitor. If the PBM can’t move enough patients quickly, the math doesn’t work, and the cheaper alternative gets locked out of the formulary.
The result is perverse. A biosimilar priced 30% below a brand-name biologic might never gain meaningful market access because the brand’s rebate strategy makes it too financially risky for PBMs to add the competitor. The FTC has noted that this dynamic also discourages biotech companies from investing in biosimilar development in the first place, since the market they’d be entering is walled off.
Transparency Remains Limited
Despite the enormous sums involved, drug rebate amounts are largely secret. Manufacturers, PBMs, and insurers treat rebate terms as proprietary. A few states have pushed for disclosure. Connecticut, Louisiana, and Nevada require PBMs to report aggregate rebate totals, but no state requires reporting at the individual drug level. Vermont requires insurers to report drug costs net of rebates, and Maine requires manufacturers to report true net prices charged to PBMs, but these remain exceptions.
At the federal level, new rules are pushing PBMs toward greater fee disclosure for employer-sponsored plans, though the details of individual rebate contracts remain largely shielded from public view. This opacity makes it difficult for employers, patients, and policymakers to evaluate whether the rebate system is genuinely lowering costs or simply redistributing money among intermediaries while list prices continue to climb.